FDA Panel Backs Gilead Hepatitis C Drug Sofosbuvir

Published October 30, 2013

FDA panel backs Gilead hepatitis C drug sofosbuvir
WASHINGTON (Reuters) – A federal advisory panel recommended on Friday that the U.S. Food and Drug Administration approve Gilead Sciences Inc's experimental hepatitis C drug sofosbuvir, paving the way for a treatment that is more effective than current … Read more on Reuters

Sanity on Obamacare
Ezra — who is still no relation to me, but a friend — does something courageous in the Washington Post: he writes about the other problems with Obamacare, in addition to the website issues. … It would have helped if the Republicans had participated … Read more on TIME

AMAG's FDA nod for Feraheme in broad iron deficiency may see further delays …
The FDA is extremely cautious about IV iron approvals, added Auerbach, a hematologist/ oncologist, and professor at Georgetown University School of Medicine, Washington, DC. The FDA approved IV iron Injectafer earlier this year (ferric carboxymaltose) … Read more on Financial Times

Pharma & Biotech Update: News for October 2013
The multidisciplinary team of doctors and scientists from multiple medical centers collaborated over a nine-month period to design a treatment plan consisting of preoperative chemo and radiation therapy, along with computerized mapping of the surgical … Read more on IPWatchdog.com